Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C15H14FNO3 |
| Molecular Weight | 275.275 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1CCC2=C(C)C(F)=CC3=C2N1C=C(C(O)=O)C3=O
InChI
InChIKey=DXKRGNXUIRKXNR-UHFFFAOYSA-N
InChI=1S/C15H14FNO3/c1-7-3-4-9-8(2)12(16)5-10-13(9)17(7)6-11(14(10)18)15(19)20/h5-7H,3-4H2,1-2H3,(H,19,20)
| Molecular Formula | C15H14FNO3 |
| Molecular Weight | 275.275 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Ibafloxacin is a fluoroquinolone antibiotic drug used in veterinary medicine. Ibafloxacin, a fluorinated 4-quinolone, is a broad spectrum antibiotic with bactericidal action against
Gram-positive and Gram-negative bacteria. Ibafloxacin is presented in the form of a tablet/oral gel
containing a racemic mixture of S- and R-ibafloxacin. The antimicrobial activity of the racemate
originates mainly from the S-enantiomer. Ibafloxacin was marketed under the brand name Ibaflin. Ibaflin tablets were intended for use in dogs for treatment of respiratory tract infections, urinary tract
infections and dermal infections caused by ibafloxacin susceptible pathogens. Ibafloxacin, is an antibiotic belonging to the class ‘fluoroquinolones’. It works by blocking an enzyme called ‘DNA gyrase’, which is important in allowing bacteria to make copies of their DNA. This enzyme is only found in bacterial cells, and does not have a similar function in animal cells. By blocking DNA gyrase, ibafloxacin prevents the bacteria from making DNA and stops them making proteins and growing, resulting in their death.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Ibaflin Approved UseDogs-tablets:
Dermal tissue infections (pyoderma – superficial and
deep, wounds, abscesses) caused by susceptible strains
of Staphylococci, E. coli and Proteus mirabilis
Acute, uncomplicated urinary tract infections (acute)
caused by susceptible strains of Staphylococci, Proteus
spp., Enterobacter spp., E. coli and Klebsiella spp.
Respiratory tract infections (upper tract) caused by
susceptible strains of Staphylococci, E. coli, and Klebsiella spp.
Cats-oral gel
Dermal infections (soft tissue infections – wounds,
abscesses) caused by susceptible pathogens such as
staphylococci, E. coli, Proteus spp. and Pasteurella
spp.
Respiratory tract infections (upper or lower tract)
caused by susceptible pathogens such as
Staphylococcus spp., E. coli, Klebsiella spp. and
Pasteurella spp. Launch Date2000 |
|||
| Curative | Ibaflin Approved UseDogs-tablets:
Dermal tissue infections (pyoderma – superficial and
deep, wounds, abscesses) caused by susceptible strains
of Staphylococci, E. coli and Proteus mirabilis
Acute, uncomplicated urinary tract infections (acute)
caused by susceptible strains of Staphylococci, Proteus
spp., Enterobacter spp., E. coli and Klebsiella spp.
Respiratory tract infections (upper tract) caused by
susceptible strains of Staphylococci, E. coli, and Klebsiella spp.
Cats-oral gel
Dermal infections (soft tissue infections – wounds,
abscesses) caused by susceptible pathogens such as
staphylococci, E. coli, Proteus spp. and Pasteurella
spp.
Respiratory tract infections (upper or lower tract)
caused by susceptible pathogens such as
Staphylococcus spp., E. coli, Klebsiella spp. and
Pasteurella spp. Launch Date2000 |
|||
| Curative | Ibaflin Approved UseDogs-tablets:
Dermal tissue infections (pyoderma – superficial and
deep, wounds, abscesses) caused by susceptible strains
of Staphylococci, E. coli and Proteus mirabilis
Acute, uncomplicated urinary tract infections (acute)
caused by susceptible strains of Staphylococci, Proteus
spp., Enterobacter spp., E. coli and Klebsiella spp.
Respiratory tract infections (upper tract) caused by
susceptible strains of Staphylococci, E. coli, and Klebsiella spp.
Cats-oral gel
Dermal infections (soft tissue infections – wounds,
abscesses) caused by susceptible pathogens such as
staphylococci, E. coli, Proteus spp. and Pasteurella
spp.
Respiratory tract infections (upper or lower tract)
caused by susceptible pathogens such as
Staphylococcus spp., E. coli, Klebsiella spp. and
Pasteurella spp. Launch Date2000 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. | 2007-11 |
|
| Development of a method for the determination of ibafloxacin in plasma by HPLC with flourescence detection and its application to a pharmacokinetic study. | 2007-06-09 |
|
| Pharmacokinetics and milk penetration of ibafloxacin after intravenous administration to lactating goats. | 2007-01 |
|
| Clinical efficacy of two ibafloxacin formulations in the treatment of canine pyoderma. | 2006-02-18 |
|
| Pharmacokinetics of ibafloxacin in healthy cats. | 2005-02 |
|
| Pharmacodynamics of ibafloxacin in micro-organisms isolated from cats. | 2005-02 |
|
| Treatment of canine pyoderma with ibafloxacin and marbofloxacin--fluoroquinolones with different pharmacokinetic profiles. | 2004-06 |
|
| In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin. | 2002-12 |
|
| Pharmacokinetics of ibafloxacin following intravenous and oral administration to healthy Beagle dogs. | 2002-04 |
|
| In-vitro activity of seventeen antimicrobial compounds against seven species of mycobacteria. | 1988-12 |
Patents
Sample Use Guides
Oral use, 15 mg ibafloxacin/kg once daily. The duration of treatment depends on the nature and severity of the infection and on the response. In most cases, a 10-day treatment course will be sufficient.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15720512
Curator's Comment: Ibafloxacin had good activity against Pasteurella spp., Escherichia coli, Klebsiella spp., Proteus spp. and Staphylococcus spp. (MIC90=0.5 ug/mL), moderate activity against Bordetella bronchiseptica, Enterobacter spp. and Enterococcus spp. (MIC50=4 ug/mL) and low activity against Pseudomonas spp. and Streptococcus spp. https://www.ncbi.nlm.nih.gov/pubmed/12485346
Escherichia coli and Pasteurella, Klebsiella and Staphylococcus spp. are commonly isolated from feline infections and all are susceptible to ibafloxacin (MIC90 < or = 0.5 ug/mL)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:27:33 GMT 2025
by
admin
on
Mon Mar 31 18:27:33 GMT 2025
|
| Record UNII |
53VPK9R0T5
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QJ01MA96
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
IBAFLIN [WITHDRAWN]
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
||
|
NCI_THESAURUS |
C795
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
IBAFLIN [WITHDRAWN]
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
91618-36-9
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
m6181
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | Merck Index | ||
|
AA-19
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
C83772
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
6398
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
53VPK9R0T5
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
IBAFLOXACIN
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
CHEMBL170052
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
100000083665
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
DTXSID8057853
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
SUB08091MIG
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY | |||
|
71186
Created by
admin on Mon Mar 31 18:27:33 GMT 2025 , Edited by admin on Mon Mar 31 18:27:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |